Several studies are currently ongoing by independent, third-party CROs. And according to Kenneth L. Waggoner, the CEO of PharmaCyte Biotech, Inc. (NASDAQ: PMCB), the first test results of the biocompatibility studies of its CypCaps clinical trial product candidate are out. The ISO 10993-4: 2017 € study evaluated the complement activation potential of empty cellulose sulphate capsules. The result demonstrated that the capsule material does not set off a significant line of the human body’s innate defense. This comes with a complement system of multiple proteins, which are circulating blood proteins. They promote immune and inflammatory responses.
Empty Cellulose Sulphate Capsules from an “In Vitro Complement Activation Study formed part of the results. These capsules are used in the treatment of pancreatic cancer. Waggoner commented, “…This is just one of the biocompatibility studies that are being performed and, in the coming weeks, we expect that the results of other studies will become available.”
The Use Of a Cellulose-Based Live Cell Encapsulation Technology
There is a dramatic change in the technological world. And PMCB has not been left behind. The biotech uses Cell-in-a-Box, a signature live-cell encapsulation technology, to develop cellular therapies for cancer and diabetes.
The technology is everyday use, whereby encapsulated cells are implanted in the patient’s tumor’s blood supply. A chemotherapy drug is then activated in the liver and administered intravenously at one-third the standard dose. The circulatory system carries the liver, where the encapsulated cells have been implanted.
PharmaCyte is Takes Part in H.C Wainwright 23rd Annual Global Investment Conference
It is the first time that PharmaCyte is participating in developing treatments for cancer, diabetes, and malignant ascites fluid. The company says it is doing this effortlessly because it does not need to raise additional capital. Thanks to H.C. Wainwright and its institutional clients.
PharmaCyte also took part in the H.C. Wainwright 23rd Annual Global Investment Conference. The company says it will continue to participate in virtual meetings.
